TegMine has identified Taiwan’s OBI as a company that can help advance its ambitions. The new deal secures TegMine the right ...

Protara, hoping to ultimately transition to a commercial stage company, snagged a chief commercial officer in Bill Conkling, ...

Sibeprenlimab targets a protein called A proliferation-inducing ligand (APRIL), and the drug is designed to limit the ...

As favor in the general market swings away from cell therapy, Immatics’ CEO is choosing to focus on what he can control: ...

Startup Clairity scored a greenlight from the FDA for the agency's first artificial intelligence tool designed to predict ...

The widely used cough suppressant dextromethorphan is an NMDA receptor antagonist. Seyltx and Atlanta-based NeurOp are ...

Corcept Therapeutics has tried to cast its recent phase 2 amyotrophic lateral sclerosis (ALS) failure in a more flattering ...

RegenXBio has shared updated phase 1/2 data on its Duchenne muscular dystrophy (DMD) gene therapy, providing evidence that ...

Cullinan Therapeutics is paying $20 million upfront for a BCMAxCD3 bispecific T cell engager that the biotech plans to pair ...

As Merck & Co., Bristol Myers Squibb and Pfizer have hopped on the PD-(L)1xVEGF bispecific bandwagon, the question becomes ...

Smiths Medical also identified three issues associated with the potential for thermal damage in affected infusion pumps. If ...

Elon Musk's brain-computer interface startup Neuralink secured $650 million in series E funding to expand patient access to ...